National Institute for Health and Care Excellence4h
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE ...
National Institute for Health and Care Excellence5d
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection TSID 12090
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Pridopidine for treating Huntington's disease TSID 12052
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [TS ID 12105]
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence6d
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) ...
National Institute for Health and Care Excellence9d
Iptacopan for treating complement 3 glomerulopathy ID6283
Suggested remit: To appraise the clinical and cost effectiveness of iptacopan within its marketing authorisation for treating complement 3 (C3) glomerulopathy.
National Institute for Health and Care Excellence9d
Iptacopan for treating complement 3 glomerulopathy ID6283
A list of downloadable documents created during development.
National Institute for Health and Care Excellence10d
Published guidance, NICE advice and quality standards
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...